The latest price target for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) was reported by Brookline Capital on December 7, 2023. The analyst firm set a price target for $0.00 expecting HEPA to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) was provided by Brookline Capital, and HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. downgraded their hold rating.

There is no last upgrade for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc.

The last downgrade for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. happened on December 7, 2023 when Brookline Capital changed their price target from N/A to N/A for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc..

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HEPION PHARMS INC by Hepion Pharmaceuticals, Inc., and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. was filed on December 7, 2023 so you should expect the next rating to be made available sometime around December 7, 2024.

While ratings are subjective and will change, the latest HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (HEPA) rating was a downgraded with a price target of $0.00 to $0.00. The current price HEPION PHARMS INC by Hepion Pharmaceuticals, Inc. (HEPA) is trading at is $0.07, which is out of the analyst’s predicted range.